Recruiting
Phase 1

PF-08642534

Sponsor:

Pfizer

Code:

NCT07731139

Conditions

Obesity

Eligibility Criteria

Sex: All

Age: 18 - 70

Healthy Volunteers: Not accepted

Interventions

Placebo

PF-08642534

Study Details

Brief summary:

This study will look at a study drug called PF-08642534 in people with obesity (have too much body weight) to see: if participants can take different amounts (doses) of the study drug in a safe way and how adults with obesity tolerate it, and how the body handles the study drug (for example, how the study drug is absorbed and removed from the body).

People who want to join the study will first go through a screening period of up to 4 weeks. Doctors will check if each person meets the study conditions, including age, body weight, and general health. People with certain medical conditions will not be able to take part in the study.

Conditions

Obesity

Study ID

NCT07731139

Start date

Jul 28, 2026

Status verified date

Sep, 2026

Completion date

Apr 21, 2027

Anticipated

Primary completion date

Apr 21, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18 - 70

Healthy Volunteers: Not accepted

Inclusion:

  • Body mass index (BMI) ≥30.0 and ≤40.0 kg/m², and with stable body weight prior to screening.
  • Participants are generally otherwise healthy but may have mild chronic conditions (eg, dyslipidemia or hypertension)

Exclusion:

\- Individuals with diabetes, significant cardiovascular, hepatic, renal, gastrointestinal, or psychiatric disorders, or conditions that may affect drug absorption or metabolism, are not eligible to participate.

Study Design

Enrollment

120 participants

Anticipated

Allocation

Randomized

Intervention Model

Sequential

Primary purpose

Basic Science

Interventions and Outcome Measures

Arms

experimental: PF-08642534

Participants will receive PF-08642534 QD

experimental: Placebo

Participants will receive matching placebo once daily (QD)

Interventions

Placebo

Participants will receive matching placebo QD

PF-08642534

Participants will receive PF-08642534 QD

Primary outcome measure

  • Incidence of treatment emergent adverse events (TEAE) [ Time Frame: Baseline up to 8 weeks after last dose ]

Central Contacts and Locations

Central contacts

Pfizer CT.gov Call Center

1-800-718-1021ClinicalTrials.gov_Inquiries@pfizer.com

Locations

Orange County Research Center

Recruiting

Lake Forest, California, United States, 92630

More Information

Sponsor

Pfizer

Last update posted

Sep 23, 2026

Last verified

Sep, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-24. This information was provided to ClinicalTrials.gov by Pfizer on 2026-09-23. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.